Lukas Biomedical (ROCO:6814) Net Margin %: -47.09% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6814 Lukas Biomedical Inc ROCO:6814
66 GF Score
Price NT$24.65
GF Value NT$21.77
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lukas Biomedical Net Margin %?

Lukas Biomedical ROCO:6814 +4.45% 66 Net Margin % is -47.09% as of Dec. 2025. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.77 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 942 Biotechnology companies, Lukas Biomedical ranks better than 55.94% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Lukas Biomedical's Net Income for the six months ended in Dec. 2025 was NT$-43.1 Mil. Lukas Biomedical's Revenue for the six months ended in Dec. 2025 was NT$91.6 Mil. Therefore, Lukas Biomedical's net margin for the quarter that ended in Dec. 2025 was -47.09%.

The historical rank and industry rank for Lukas Biomedical's Net Margin % or its related term are showing as below:

ROCO:6814' s Net Margin % Range Over the Past 10 Years
Min: -49.72   Med: -24.05   Max: -4.57
Current: -47.71

ROCO:6814's Net Margin % is ranked better than
55.94% of 942 companies
in the Biotechnology industry
Industry Median: -88.295 vs ROCO:6814: -47.71

Lukas Biomedical  (ROCO:6814) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Lukas Biomedical Net Margin % Related Terms

Lukas Biomedical Net Margin % Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical Net Margin % Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial -31.40 -27.10 -20.43 -49.72 -47.71

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.77 -41.74 -58.13 -48.35 -47.09

ROCO:6814 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Lukas Biomedical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lukas Biomedical Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Net Margin % distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's Net Margin % falls into.


ROCO:6814
66GF Score
Lukas Biomedical Inc ROCO:6814
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Lukas Biomedical's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-85.633/179.493
=-47.71 %

Lukas Biomedical's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-43.124/91.575
=-47.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -47.09% mean?
Lukas Biomedical (ROCO:6814) has a Net Margin % of -47.09% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Lukas Biomedical and its competitors. According to the industry distribution chart, Lukas Biomedical ranks #415 out of 942 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Lukas Biomedical's Net Margin % too high?
Lukas Biomedical's current Net Margin % is -47.09%. Based on the distribution chart, Lukas Biomedical ranks #415 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #415 out of 942 companies for Net Margin %. This puts Lukas Biomedical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lukas Biomedical and its competitors. Lukas Biomedical's current Net Margin % is -47.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.65 — trading 13.2% above its estimated fair value. The current Net Margin % is -47.09%. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Net Margin % is -47.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$24.65 is trading 13.2% above its estimated GF Value™ of NT$21.77. GuruFocus considers Lukas Biomedical to be Modestly Overvalued.

Key valuation signals for ROCO:6814:

  • Net Margin %: -47.09%
  • GF Value™: NT$21.77 vs. price of NT$24.65 (13.2% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score

Get the complete analysis for ROCO:6814

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.65
Price
NT$21.77
GF Value